We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sorting and Selecting Cancer Cells by Their Motility Will Advance Understanding of Metastatic Processes

By LabMedica International staff writers
Posted on 03 Jun 2015
In order to develop a better understanding of the mechanisms that cause some cancer cells to break away from the primary tumor and migrate to other parts of the body, a team of cancer researchers has created an instrument for sorting and selecting cancer cells based on their motility.

Tumor cell migration toward and into capillaries is an early and key event in cancer metastasis, yet not all cancer cells are imbued with the same capability to do so. More...
This heterogeneity within a tumor is a fundamental property of cancer.

Conventional in vitro migration platforms have so far related to cell populations as an aggregate, which has led to a masking of intrinsic differences among cells. While some migration assays have reported the ability to resolve single cells, these platforms did not provide for selective retrieval of the distinct migrating and non-migrating cell populations for further analysis.

Therefore, to study the intrinsic differences in cells responsible for chemotactic heterogeneity, investigators at the University of Michigan (Ann Arbor, USA) developed a single-cell migration platform so that individual cells’ migration behavior could be studied and the heterogeneous population sorted based upon chemotactic phenotype. Furthermore, after migration, highly chemotactic and non-chemotactic cells were retrieved and proved viable for later molecular analysis of their differences.

In addition, as described in a paper published in the May 18, 2015, online edition of the journal Scientific Reports, the investigators modified the migration channel to resemble lymphatic capillaries to better understand how certain cancer cells are able to move through geometrically confining spaces.

"This work demonstrates an elegant approach to the study of cancer cell metastasis by combining expertise in engineering and biology," said senior author Dr. Euisik Yoon, professor of electrical engineering, computer science, and biomedical engineering at the University of Michigan. "In past decades, engineers have developed biological tools with better resolution, higher sensitivity, selectivity, and higher throughput. However, without compelling applications, these engineering tools have little practical relevance. The goal of our lab is to develop tools that can be widely disseminated to the biology community to eventually impact clinical care for patients."

Related Links:

University of Michigan



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.